{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:17:25Z","timestamp":1790057845510,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers","award":["NCT02277743"],"award-info":[{"award-number":["NCT02277743"]}]},{"name":"Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers","award":["NCT02277769"],"award-info":[{"award-number":["NCT02277769"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jdermsci.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:43:18Z","timestamp":1552394598000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"title":["Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)"],"prefix":"10.1016","volume":"94","author":[{"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"L. Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2019.02.002_bib0005","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J. Clin. Cell. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jdermsci.2019.02.002_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ad.2012.03.008","article-title":"Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study","volume":"104","author":"S\u00e1nchez-P\u00e9rez","year":"2013","journal-title":"Actas. Dermosi\ufb01liogr."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J. Invest. Derm."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/jamadermatol.2016.1978","article-title":"Research gaps in quality of life and economic burden of atopic dermatitis: the national eczema association burden of disease audit","volume":"152","author":"Drucker","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.det.2017.02.004","article-title":"Patient burden of atopic dermatitis","volume":"35","author":"Sibbald","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0055","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2340\/00015555-2480","article-title":"What factors are important to patients when assessing treatment response: an international cross-sectional survey","volume":"97","author":"Von Kobyletzki","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0070","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers in Type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2015","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) Part 1","volume":"26","author":"Ring","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0095","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"MacDonald","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0100","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0120","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weiller","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0130","series-title":"Self-reported Population Health: An International Perspective Based on EQ-5D","author":"Szende","year":"2014"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","article-title":"Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials","volume":"7","author":"Simpson","year":"2017","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjd.14773","article-title":"Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative)","volume":"175","author":"Chalmers","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0145","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","article-title":"Phenotype of atopic dermatitis subjects with a history of eczema herpeticum","volume":"124","author":"Beck","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0150","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2006.08.008","article-title":"Mechanism of HBD-3 deficiency in atopic dermatitis","volume":"121","author":"Howell","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0155","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaci.2011.02.010","article-title":"Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-\u03b3 response","volume":"127","author":"Leung","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","article-title":"Bacterial and viral infections in atopic dermatitis: a comprehensive review","volume":"51","author":"Ong","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2340\/00015555-1465","article-title":"Sensitization to skin-associated microorganisms in adult patients with atopic dermatitis is of importance for disease severity","volume":"93","author":"Sonesson","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0170","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2015.07.052","article-title":"Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis","volume":"137","author":"Tauber","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11882-015-0567-4","article-title":"The role of the skin microbiome in atopic dermatitis","volume":"15","author":"Williams","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0180","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2003.07.001","article-title":"Viral infections in atopic dermatitis: pathogenic aspects and clinical management","volume":"112","author":"Wollenberg","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","article-title":"Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases","volume":"49","author":"Wollenberg","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0190","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0195","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0205","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0210","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.02.002_bib0215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119300283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119300283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:49:04Z","timestamp":1760330944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181119300283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0923181119300283"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.02.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}